Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
2015;309:E256264
The combination exists in clinical practice based on pharmacological reasoning and extrapolation from related studies, not direct evidence
Package pricing is available and brings the per session cost down
While some trials show no major changes in BMD, others suggest slight improvements in bone turnover markers: Trials of liraglutide and exenatide generally show stable BMD over 612 months Certain populations such as postmenopausal women or individuals with rapid weight loss may show changes in bone markers like osteocalcin and P1NP However, most of these studies are small, short-term, or not powered for skeletal endpoints
The street mean target of around $271 implies roughly 30% upside from the current price of around $208
US$ 26.49
US$ 23.28
US$ 25.55
US$ 23.78
US$ 21.21
